India Glycols: Material Update on Ennature Bio Pharma Scheme of Arrangement

M&A / JV — · In regulatory review· ✓ Verified

India Glycols Limited notified both NSE and BSE of a material update concerning a Scheme of Arrangement with Ennature Bio Pharma Limited. The observation letters (NSE/LIST/48932 of 17 November 2025 and BSE DCS/AMAL/TS/R37/3905/2025-26 of 19 November 2025) were issued by the stock exchanges, indicating regulatory consideration of the scheme's listing implications and disclosure requirements. The exact consideration, demerger/merger mechanics, and NCLT bench reference are not detailed in the available source material.

Why it mattersObservation letters from both stock exchanges mark regulatory approval of the scheme's listed-entity disclosure obligations; subsequent step is likely NCLT sanction or scheme implementation conditional on shareholder/creditor approval.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals